Administration Of Ritonavir Booster
03/06/2022 14:22
June 3 (Reuters) - Sorrento Therapeutics Inc SRNE.O :
* SORRENTO THERAPEUTICS ANNOUNCES FIRST SUBJECT DOSED IN A
PHASE I
CLINICAL STUDY OF STI-1558, AN ORAL MPRO INHIBITOR AS A
STANDALONE TREATMENT AND PREVENTION OF COVID-19 WITHOUT
CO-ADMINISTRATION OF RITONAVIR BOOSTER
Source text for Eikon: ID:nGNX7TlyLc
Further company coverage: SRNE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sorrento Therapeutics
See all newsBrief: Scilex Holding Says US Bankruptcy Court Extended Lockup Period On Shares Of Scilex Stock
Company's PO box allows it to file for bankruptcy in Texas, judge rules
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute (updated)
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute
Brief: Sorrento Therapeutics Reduced U.S. Headcount From 215 To 128 on Sept. 20